C76 treatment markedly inhibited PAH progression and occlusive pulmonary vascular remodeling and promoted the survival of Egln1Tie2 mice indicating that inhibition of HIF-2α is a novel effective therapeutic strategy for PAH in patients [13]. This evidence concerns the gene EPAS1 and pulmonary arterial hypertension.